Skip to main content
logo
Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
17.10
-0.18 (-1.04%)
Jul 24, 2026, 4:00 PM EDT - Market closed

Cullinan Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
-----18.94
Revenue Growth
------
Gross Profit
-----18.94
Operating Income
-240.35-241.65-196.92-191.09144.65-67.95
Net Income
-221.04-219.88-167.38-153.16111.21-65.57
Earnings Per Share
-3.36-3.36-2.78-3.212.38-1.52
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
351.89377.9398.98467.07467.29290.47
Total Debt
2.382.682.153.595.010
Net Cash (Debt)
349.5375.21396.83463.48462.28290.47
Net Cash Growth
15.73%-5.45%-14.38%0.26%59.15%38.18%
Net Cash Per Share
5.316.357.389.719.916.74

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-178.64-175.75-145.3-134.28-126.66-43.43
Capital Expenditures
--0.05--0.21-1.13-
Free Cash Flow
-178.64-175.8-145.3-134.48-127.8-43.43
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-----100.00%
Operating Margin
------358.73%
Pretax Margin
------356.25%
Profit Margin
------356.25%
FCF Margin
------229.28%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJul '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PE Ratio
----4.43-
Forward PE
-6.706.706.706.70-
PS Ratio
-----36.08